(Q37358267)

19 August 2017

Bisphosphonates inhibit the adhesion of breast cancer cells to bone matrices in vitro (English)

1 reference

19 August 2017

1 reference

van der Pluijm G

1

1 reference

19 August 2017

Vloedgraven H

2

1 reference

19 August 2017

van Beek E

3

1 reference

19 August 2017

van der Wee-Pals L

4

1 reference

19 August 2017

Löwik C

5

1 reference

19 August 2017

Papapoulos S

6

1 reference

19 August 2017

language of work or name

English

0 references

publication date

1 August 1996

1 reference

Journal of Clinical Investigation

19 August 2017

1 reference

19 August 2017

98

1 reference

19 August 2017

698-705

1 reference

19 August 2017

3

1 reference

Resorption of bone by isolated rabbit osteoclasts

19 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=507479

Breast tumor cell lines from pleural effusions

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=507479

The clinical course of bone metastases from breast cancer

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=507479

Osteolytic bone metastases in breast carcinoma pathogenesis, morbidity and bisphosphonate treatment

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=507479

Rationale for the use of bisphosphonates in bone metastases

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=507479

Mechanisms of osteolytic bone destruction

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=507479

Bisphosphonates. Pharmacology and use in the treatment of tumour-induced hypercalcaemic and metastatic bone disease

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=507479

Bone metastases in breast cancer, prostate cancer and myeloma.

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=507479

Osteolytic bone metastasis in breast cancer

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=507479

Bone destruction in cancer.

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=507479

Mechanisms involved in the metastasis of cancer to bone

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=507479

Stimulation of bone resorption results in a selective increase in the growth rate of spontaneously metastatic Walker 256 cancer cells in bone

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=507479

Bone sialoprotein peptides are potent inhibitors of breast cancer cell adhesion to bone.

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=507479

Bisphosphonate risedronate reduces metastatic human breast cancer burden in bone in nude mice

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=507479

Quantitative morphometric evaluation of the inhibitory activity of new aminobisphosphonates on bone resorption in the rat.

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=507479

Preclinical pharmacology of CGP 42'446, a new, potent, heterocyclic bisphosphonate compound

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=507479

Long-term controlled trial with diphosphonate in patients with osteolytic bone metastases.

26 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=507479

Two modes of action of bisphosphonates on osteoclastic resorption of mineralized matrix

26 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=507479

Migration and phenotypic transformation of osteoclast precursors into mature osteoclasts: the effect of a bisphosphonate.

26 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=507479

The osteoclast functional antigen, implicated in the regulation of bone resorption, is biochemically related to the vitronectin receptor

26 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=507479

Disodium 1-hydroxy-3-(1-pyrrolidinyl)-propylidene-1,1-bisphosphonate (EB-1053) is a potent inhibitor of bone resorption in vitro and in vivo

26 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=507479

The effect of supportive pamidronate treatment on aspects of quality of life of patients with advanced breast cancer

26 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=507479

Effects of bisphosphonates on isolated rat osteoclasts as examined by reflected light microscopy

2 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=507479

Interactions between the bone matrix proteins osteopontin and bone sialoprotein and the osteoclast integrin alpha v beta 3 potentiate bone resorption

2 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=507479

Reduced morbidity from skeletal metastases in breast cancer patients during long-term bisphosphonate (APD) treatment

5 November 2018

1 reference

12 December 2020

Relationship of bone destruction in skeletal metastases to osteoclast activation and prostaglandins

1 reference

12 December 2020

Enhancement of the inhibitory action of APD on the transformation of osteoclast precursors into resorbing cells after dimethylation of the amino group

1 reference

12 December 2020

Application of an in vitro model and a clinical protocol in the assessment of the potency of a new bisphosphonate

1 reference

12 December 2020

Antiresorptive dose-response relationships across three generations of bisphosphonates

1 reference

12 December 2020

BM 21.0955, a potent new bisphosphonate to inhibit bone resorption

1 reference

12 December 2020

Rat osteoclasts adhere to a wide range of RGD (Arg-Gly-Asp) peptide-containing proteins, including the bone sialoproteins and fibronectin, via a beta 3 integrin

1 reference

12 December 2020

Double-blind controlled trial of oral clodronate in patients with bone metastases from breast cancer

1 reference

12 December 2020

Palliative pamidronate treatment in patients with bone metastases from breast cancer

1 reference

12 December 2020

Prophylactic treatment of skeletal metastases, tumor-induced osteolysis, and hypercalcemia in rats with the bisphosphonate Cl2MBP

1 reference

12 December 2020

Integrins and osteoclastic resorption in three bone organ cultures: differential sensitivity to synthetic Arg-Gly-Asp peptides during osteoclast formation

1 reference

12 December 2020

Development of skeletal metastases

1 reference

12 December 2020

Direct resorption of bone by human breast cancer cells in vitro

1 reference

12 December 2020

Mechanisms of lytic and blastic metastatic disease of bone

1 reference

12 December 2020

Mechanisms of bone destruction in the development of skeletal metastases

1 reference

12 December 2020

Identifiers

DOI

10.1172/JCI118841

1 reference

19 August 2017

1 reference

19 August 2017

1 reference